Cargando…

Risk prediction model for epithelial ovarian cancer using molecular markers and clinical characteristics

BACKGROUND: A high-quality risk prediction model is urgently needed for the clinical management of ovarian cancer. However most existing models are solely based on clinical parameters, and molecular classifications in recent reports are still being debated. This study aimed to establish a risk predi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Meiying, Zhuang, Guanglei, Sun, Xiangjun, Shen, Yanying, Zhao, Aimin, Di, Wen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618052/ https://www.ncbi.nlm.nih.gov/pubmed/26490766 http://dx.doi.org/10.1186/s13048-015-0195-6

Ejemplares similares

TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer
por: Zhang, Meiying, et al.
Publicado: (2017)

A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients
por: Zhang, Meiying, et al.
Publicado: (2014)

Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer
por: Zhang, Shengzhe, et al.
Publicado: (2015)

Development and external validation of nomograms for predicting individual survival in patients with ovarian clear cell carcinoma
por: Liu, Xiaoshi, et al.
Publicado: (2023)

Development and Validation of a Nomogram to Predict the Probability of Venous Thromboembolism in Patients with Epithelial Ovarian Cancer
por: Wang, Yuhan, et al.
Publicado: (2022)

PAX8 regulon in human ovarian cancer links lineage dependency with epigenetic vulnerability to HDAC inhibitors
por: Shi, Kaixuan, et al.
Publicado: (2019)

A VEGF-dependent gene signature enriched in mesenchymal ovarian cancer predicts patient prognosis
por: Yin, Xia, et al.
Publicado: (2016)

Polygenic risk modeling for prediction of epithelial ovarian cancer risk
por: Dareng, Eileen O., et al.
Publicado: (2022)

BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1
por: Zhang, Zhenfeng, et al.
Publicado: (2016)

Ovarian cancer risk score predicts chemo-response and outcome in epithelial ovarian carcinoma patients
por: Lu, Hsiao-Yun, et al.
Publicado: (2020)

Therapeutic targeting of CPSF3-dependent transcriptional termination in ovarian cancer
por: Shen, Peiye, et al.
Publicado: (2023)

Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk
por: Dareng, Eileen O., et al.
Publicado: (2022)

Overexpression of TRIM44 is an independent marker for predicting poor prognosis in epithelial ovarian cancer
por: Liu, Shuang, et al.
Publicado: (2018)

Predictive equation of metastasis in patients with malignant ovarian epithelial tumors with the Ca-125 marker
por: Sánchez Vega, Juan Fernando, et al.
Publicado: (2018)

MicroRNA characteristics in epithelial ovarian cancer
por: Prahm, Kira Philipsen, et al.
Publicado: (2021)

Role of tumour markers in monitoring epithelial ovarian cancer
por: Meyer, T, et al.
Publicado: (2000)

Concomitant BET and MAPK blockade for effective treatment of ovarian cancer
por: Jing, Ying, et al.
Publicado: (2015)

Vesicular-Bound HLA-G as a Predictive Marker for Disease Progression in Epithelial Ovarian Cancer
por: Schwich, Esther, et al.
Publicado: (2019)

Magnetic resonance imaging radiomics to differentiate ovarian sex cord-stromal tumors and primary epithelial ovarian cancers
por: Cheng, Meiying, et al.
Publicado: (2023)

Sialyl Tn as a prognostic marker in epithelial ovarian cancer.
por: Kobayashi, H., et al.
Publicado: (1992)

Exosomal microRNAs as tumor markers in epithelial ovarian cancer
por: Pan, Chi, et al.
Publicado: (2018)

Evaluation of Sialyl-Lactotetra as a Marker for Epithelial Ovarian Tumors
por: Barone, Angela, et al.
Publicado: (2020)

Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors
por: Zhang, Shengzhe, et al.
Publicado: (2018)

PAX8 is a potential marker for the diagnosis of primary epithelial ovarian cancer
por: Chai, Hong-Juan, et al.
Publicado: (2017)

Correlation of Molecular Tumor Markers CA125, HE4, and CEA with the Development and Progression of Epithelial Ovarian Cancer
por: Wan, Qiuhua, et al.
Publicado: (2021)

Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer
por: Furrer, Daniela, et al.
Publicado: (2019)

Utility of Preoperative Inflammatory Markers to Distinguish Epithelial Ovarian Cancer from Benign Ovarian Masses
por: Li, Lian, et al.
Publicado: (2021)

Diagnosis and preoperative predictive value of serum HE4 concentrations for optimal debulking in epithelial ovarian cancer
por: YANG, ZHIJUN, et al.
Publicado: (2013)

GTW inhibits the Epithelial to Mesenchymal Transition of Epithelial Ovarian Cancer via ILK/AKT/GSK3β/Slug Signalling Pathway
por: Feng, Ying, et al.
Publicado: (2021)

EphA8 is a prognostic marker for epithelial ovarian cancer
por: Liu, Xiaoqin, et al.
Publicado: (2016)

The Molecular Landscape Influencing Prognoses of Epithelial Ovarian Cancer
por: Liu, Chao-Lien, et al.
Publicado: (2021)

Prognostic Characteristics of MACC1 Expression in Epithelial Ovarian Cancer
por: Jeong, Hoiseon, et al.
Publicado: (2018)

Construction of Metabolic Molecular Classification and Immune Characteristics for the Prognosis Prediction of Ovarian Cancer
por: Wang, Kexin, et al.
Publicado: (2022)

Adipocytes: active facilitators in epithelial ovarian cancer progression?
por: Dai, Lan, et al.
Publicado: (2020)

Molecular Signature for Lymphatic Invasion Associated with Survival of Epithelial Ovarian Cancer
por: Paik, E Sun, et al.
Publicado: (2018)

ARRDC3 as a Diagnostic and Prognostic Biomarker for Epithelial Ovarian Cancer Based on Data Mining
por: Chen, Yanli, et al.
Publicado: (2021)

Thrombin promotes epithelial ovarian cancer cell invasion by inducing epithelial-mesenchymal transition
por: Zhong, Yi-Cun, et al.
Publicado: (2013)

Establishment and verification of the nomogram that predicts the 3-year recurrence risk of epithelial ovarian carcinoma
por: Hu, Jun, et al.
Publicado: (2020)

TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers
por: Ghisoni, Eleonora, et al.
Publicado: (2019)

Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy
por: Bai, Huimin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1tsfcncmo2ngm8tsc1fbn4c8mf